Highlights
-
•
We examined rates of SUD and psychiatric disorders in people with TUD, obesity, and both health conditions.
-
•
People with TUD and obesity have lower rates of SUD than people with TUD in the normal weight range.
-
•
Obesity (BMI>30) is associated with lower risk of SUD.
Keywords: Obesity, Tobacco use disorder (TUD), Substance use disorder (SUD), Multimorbidity
Abstract
Background
Multimorbidity is linked to worse health outcomes than single health conditions. However, recent studies show that obesity may reduce the risk of developing substance use disorders (SUDs), particularly in vulnerable populations. We investigated how comorbid obesity and tobacco use disorder (TUD) relate to the risk of SUDs and psychiatric conditions.
Methods
Data was used from 36,309 individuals who completed the National Epidemiological Survey on Alcohol and Related Conditions - Wave III. Individuals who met the DSM-5 criteria for TUD in the last year were defined as the TUD group. Obesity was defined as having a body mass index (BMI) greater than 30 kg/m2. Using this information, individuals were grouped into categories, with people being identified as either having obesity, TUD, both obesity and TUD, or not having either obesity or TUD (comparison). Groups were compared against their comorbid diagnoses of either an additional SUD or psychiatric conditions.
Results
Controlling for demographic characteristics, we found that individuals with obesity including those individuals with TUD, had lower rates of comorbid SUD diagnosis than individuals with TUD alone. Additionally, individuals with combined TUD and obesity, and those with TUD alone, had the highest rates of comorbid psychiatric disorder diagnosis.
Conclusions
The current study aligns with previous research suggesting that obesity may reduce risk of substance use disorders, even in individuals who have other risk factors promoting harmful substance use (e.g., tobacco use). These findings may inform targeted intervention strategies for this clinically relevant subpopulation.
1. Introduction
Multimorbidity affects up to 1/3 of all adults and 1/2 of those with preexisting chronic health conditions, resulting in increased healthcare visits, hospital stays, and costs (GBD, 2019; Han et al., 2018; Skou et al., 2022). Multimorbidity increases the risk of death, lowers quality of life, and leads to poorer health outcomes compared to having a single condition (Bhalla et al., 2018). These conditions also disproportionately affect lower socioeconomic status communities (Katikireddi et al., 2017; Salisbury, 2012; Skou et al., 2022). Additionally, individuals with multimorbidities are also 2–3 times more likely to experience depression (Fortin et al., 2004, 2006; Read et al., 2017). To improve treatment approaches, it is important to further characterize and understand multimorbidity as most healthcare systems focus on single conditions and, thus, are not equipped to handle them (Atun, 2015).
Two conditions that are of particular interest to the current study are obesity and tobacco use disorder (TUD) because of their outsized impact on both physical and mental health. Each disorder accounts for more preventable deaths, particularly in the developed world, than most other conditions combined (Powell-Wiley et al., 2021; CDC, 2010). The co-occurence of these conditions is common, impacting an estimated 3–7% of the global population (Healton et al., 2006; Rupprecht et al., 2015; Dare et al., 2015; Roberts and Rosenheck, 2020).
In 2021, approximately 11% of individuals who were 12 years old or older (approximately 4.3 million) used a tobacco or nicotine product in the US in the past month (SAMHSA, 2021). Tobacco use alone leads to the development of a multitude of health issues and is one of the leading causes of death for US citizens and costs nearly $600 billion annually (CDCTobaccoFree, 2021). Additionally, tobacco use is associated with increased incidence of other substance use issues (Schulte, et al., 2014; Smith et al., 2014), as well as greater relapse rates in those with other substance use disorders (SUDs; Weinberger et al., 2017). Approximately 35% of smokers meet criteria for a psychiatric condition (CDC, 2020). However, it should be noted that for individuals expressing multiple mental health disorders, smoking rates can be as high as 60%+ (Prochaska et al., 2017).
Obesity, as defined as a BMI of 30 kg/m2 or above, in the United States has a reported prevalence of nearly 42% in the adult population with a reported annual medical cost of over $147 billion (CDC, 2022). Obesity increases the risk of numerous diseases (e.g., heart disease, diabetes) and is linked to nearly 2.8 million deaths worldwide annually (WHO, 2021). In regards to mental health, for persons with obesity, mood and anxiety disorders appear most prevalent, with an approximate 25% increase in risk of either when compared to individuals at lower weight ranges (Simon et al., 2006; Mather et al., 2009; Luppino et al., 2010). These disorders also appeared to be more prevalent in women with obesity compared to men with obesity (Scott et al., 2008).
Some evidence suggests that co-occurrence of obesity and TUD can put individuals at an even greater risk for disease and psychiatric conditions than does either condition occurring alone. Indeed, a recent report published by Roberts and Rosencheck (2020) based on national data from Veterans treated in the Veterans Health Administration (VHA) showed that individuals who were obese and also diagnosed with a TUD had higher rates of comorbid health and psychiatric conditions (e.g. bipolar and personality disorder) than either TUD or obesity alone. However, a surprising finding in the same study, revealed that those individuals who were characterized as obese had the lowest risk of a comorbid SUD. These results suggest the possibility that people with obesity, even those with a comorbid TUD, may have an overall reduced risk for SUD diagnosis when compared to individuals diagnosed with a TUD alone. Similarly, a study conducted by Pickering et al. (2011) found that both men and women who were either categorized as overweight or obese were at a decreased risk for being diagnosed with alcohol use disorder (AUD) and some other SUDs. Though the exact mechanism for this reduced risk of substance use issues in individuals who are obese remains somewhat unclear, it is speculated that the reward pathways that mediate the reinforcing properties of drugs of abuse are activated in a similar and likely competitive manner by highly rewarding foods; often referred to as the food-drug competition hypothesis (Kleiner et al., 2004; Warren and Gold, 2007; Nolan, 2013; Sansone and Sansone, 2013; Volkow and Baler, 2015; Michaud et al., 2017). Additional support for this phenomenon comes from the food-drug substitution hypothesis where individuals may substitute one highly rewarding substance, such as food, with another, such as drugs of abuse (Ivezaj et al., 2012; Kim et al., 2021). This appears to be particularly common in post-operative bariatric patients (Azam et al., 2018). These theories have been used to support the proposal of food addiction as a distinct clinical diagnosis, but further research is needed (Shaffer et al., 2004; Barry et al., 2009; Avena et al., 2012; Gearhardt et al., 2018; Hoover et al., 2022; Vasiliu, 2022). These theories, however, do not support the co-expression of both conditions. However, this may be explained by dysregulated reward sensitivity which is particularly common in more extreme BMI ranges (Reynolds, 2006; Stanger et al., 2013; Rupprecht et al., 2015). Additionally, the distinct neurobiological pathways of both TUD and obesity, which ultimately lead to activation of the dopaminergic reward system, may also contribute to their co-occurrence (Benowitz, 2009; Berthoud, 2002). The co-expression of obesity with TUD is further complicated by the appetite suppressing effects of nicotine (Audrain-McGovern and Benowitz, 2011); however people who smoke, including those with obesity, often report that weight management is a motive for their continued tobacco use (White et al., 2007; White, 2012).
The current study aims to extend the findings originally reported in Roberts and Rosenheck (2020) by further characterizing multimorbid expression of TUD and obesity using the nationally representative NESARC-III dataset which uses the gold-standard AUDADIS (Grant et al., 2014). We hypothesized that people with TUD alone will be more likely to meet criteria for multimorbid SUD compared to those with TUD whose BMI falls in the obese range. Additionally, based on previous findings (Pickering et al., 2011; Roberts and Rosenheck, 2020), we expected that people with TUD and obesity would show higher rates of other psychiatric disorders compared to those with either disorder alone. The prior study investigating this specific comorbidity relied on health records from the VHA, which have limitations due to non-randomized sampling and reliance on unstandardized diagnoses (Vassar and Holzmann, 2013). It is important to address these limitations using alternative and representative data sources to confirm the veracity of these surprising results. Additionally, the previous study did not include a healthy comparison group (i.e., those without either obesity or tobacco use), and such a comparison group helps to better contextualize the risk associated with each condition and their multimorbid expression.
2. Materials and methods
2.1. Data source
Data for this study was collected from the NESARC-III, which is a national survey conducted by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) (Grant et al., 2014). The sample (n = 36,309) included noninstitutionalized civilians who were 18 years or older from the United States. Participants who gave informed consent completed an in-person computer assisted interview (Alcohol Use Disorder and Associated Disabilities Interview Schedule-5; AUDADIS-5). The AUDADIS-5 is a valid measure of SUDs and TUDs (Hasin et al., 2015). Data weights were applied to adjust for oversampling and nonresponse. Additional methodological details on the NESARC-III are provided elsewhere (Grant et al., 2014).
2.2. Covariates/demographics
Demographic variables were selected because of their probable association with obesity and TUD and included sex, race/ethnicity, age, income, nativity, marital status, census region, urban/rural residence, and education. These demographic covariates were included in all models. All demographic variables were treated as categorical variables except income. Income was treated as a continuous category ranging from 1 (>$4999) to 17 (<$100,000). Please see Table 1 for a detailed breakdown of all demographic characteristics.
Table 1.
Weighted demographic variables.
| 1. Comparison Group | 2. TUD | 3. Obese | 4. TUD + Obese | |
|---|---|---|---|---|
| Sex | % | % | % | % |
| Male | 46.76 | 57.05 | 46.12 | 53.86 |
| Female | 53.24 | 42.95 | 53.88 | 46.14 |
| Race/Ethnicity | % | % | % | % |
| White, non-Hispanic | 65.11 | 75.24 | 62.45 | 70.4 |
| Black, non-Hispanic | 9.84 | 10.66 | 16.06 | 14.63 |
| American Indian/Alaska Native, non-Hispanic | 1.11 | 2.220 | 1.98 | 2.52 |
| Asian/Native Hawaiian/Other Pacific Islander, non-Hispanic | 8.31 | 3.64 | 2.110 | 2.17 |
| Hispanic, any race | 15.61 | 8.23 | 17.4 | 10.27 |
| Age | % | % | % | % |
| < 24 | 12.93 | 16.57 | 7.85 | 8.78 |
| 25 to 34 | 16.59 | 22.68 | 14.45 | 22.42 |
| 35 to 44 | 15.87 | 16.94 | 18.54 | 23.75 |
| 45 to 59 | 24.73 | 29.5 | 30.42 | 33.76 |
| 60+ | 27.87 | 14.3 | 28.74 | 11.3 |
| Income | M (SE) | M (SE) | M (SE) | M (SE) |
| 7.85 (0.074) | 6.52 (0.089) | 7.73 (0.080) | 6.71 (0.148) | |
| Nativity | % | % | % | % |
| United States | 79.55 | 92.93 | 86.8 | 94.58 |
| Non-United States | 20.45 | 7.07 | 13.19 | 5.42 |
| Marital Status | % | % | % | % |
| Married | 53.62 | 34.8 | 57.1 | 43.9 |
| Living with someone as if married | 5.69 | 10.58 | 5.36 | 11.86 |
| Widowed | 6.54 | 4.2 | 5.66 | 2.77 |
| Divorced | 8.82 | 16.68 | 11.34 | 15.04 |
| Separated | 2.35 | 4.63 | 2.78 | 4.52 |
| Never married | 22.97 | 29.11 | 17.76 | 21.91 |
| Census Region | % | % | % | % |
| Northeast | 19.33 | 16.38 | 16.7 | 17.77 |
| Midwest | 19.62 | 24.1 | 23.430 | 24.800 |
| South | 35.270 | 39.910 | 38.91 | 40.03 |
| West | 25.78 | 19.6 | 20.95 | 17.4 |
| Urban or Rural Residence | % | % | % | % |
| Urban | 81.64 | 73.63 | 76.74 | 72.39 |
| Rural | 18.36 | 26.37 | 23.26 | 27.61 |
| Education | % | % | % | % |
| Less than high school | 10.77 | 18.19 | 13.55 | 18.06 |
| High school | 22.25 | 33.27 | 27.22 | 34.44 |
| Some college | 31.03 | 35.54 | 35.41 | 36.54 |
| Bachelor's degree | 22.55 | 9.48 | 15.57 | 8.03 |
| Graduate degree | 13.39 | 3.58 | 8.25 | 2.93 |
2.3. Classification strategy
Participants were stratified into the following four groups based on their BMI and TUD status:
Comparison: Participants who did not meet the past-year criteria for a TUD and had a BMI below 30 kg/m2 were categorized into the comparison group.
TUD: Those individuals classified as TUD were those who met the DSM-5 criteria for a TUD in the last year using the AUDADIS-5 and also had a BMI < 30 kg/m2.
Obese: Participants’ self-reported height and weight were used to calculate BMI. A person with obesity was defined as having a BMI of greater than or equal to 30 (calculated as weight in kilograms divided by the square of an individual's height in meters) which is equivalent to class 1 obesity or greater (CDC, 2022).
TUD + Obese: Participants who met the past-year criteria for TUD (as described above) and had a BMI greater than or equal to 30 kg/m2 were classified as an individual with obesity and a TUD.
2.4. Substance use
DSM-5 SUDs were evaluated using the AUDADIS. All SUD diagnoses were based on symptoms occurring in the past 12 months. Results included AUD, cannabis use disorder (CUD), other SUDs (i.e., inhalant/solvent, club drug, heroin, hallucinogen, stimulant, or sedative). We also calculated a SUD count outcome that indicated how many separate SUDs for which the individual met criteria.
2.5. Mental health
DSM-5 mental health disorders were evaluated using the AUDADIS. Diagnosis for each disorder was based on symptoms occurring in the past 12 months. Results included diagnoses for mood disorders (i.e., major depressive, dysthymia, bipolar 1), anxiety disorders (i.e., agoraphobia, panic disorder, social phobia, specific phobia, generalized anxiety, and posttraumatic stress) and personality disorders (i.e., schizotypal, borderline, antisocial personality). We also included a count variable that indicated the number of diagnoses for which the individual met criteria.
2.6. Missing data
In cases where participants are missing demographic variables (e.g., age, race) NESARC-III adds logically assigned values (detailed method of logical assignment is reported in Grant et al., 2014). Missing data rates were low (n=552, 1.5% of sample with some missing data). Height and weight were the most common missing variables. We used a complete case analysis approach, such that participants with any missing data were excluded from further analysis.
2.7. Statistical analysis
Models were generated using the “survey” package in R (version 4.1.3). All covariates discussed above were included in all analyses (i.e., sex, race/ethnicity, age, income, nativity, marital status, census region, urban/rural residence, and education). The primary analyses examined the differences between individuals who met criteria for obesity, TUD, or both (obesity +TUD) to a comparison group on a variety of SUDs and Mental Health Disorders (described above). All analyses incorporated the stratification, clustering, and unequal weighting of the sampling design. Binary logistic regression was used to analyze binary nominal outcome variables (i.e., psychiatric conditions, any SUD). All count based outcomes were analyzed using quasipoisson regression. We report adjusted odds ratios (aOR; logistic models) and adjusted rate ratios (aRR; quasipoisson models) and 95% confidence intervals. A priori pairwise contrasts were conducted to probe the relative differences in risk/rate between groups. The significance threshold for these contrasts was set at p<.05. We also conducted a supplemental analysis to examine these associations among people with different degrees of obesity (i.e., underweight, healthy weight, overweight, and Class 1 & 2). While interpreting these models is limited by the proliferation of groups limiting cell sizes, we include them to provide some insight into how obesity severity may affect the described associations. These models are presented in a supplemental table.
3. Results
3.1. Sample characteristics
All demographic information is presented in Table 1. The sample included 36,309 individuals. 2135 (5.88%) individuals were diagnosed with a TUD and also reported BMI in the obese range (30+ kg/m2; TUD + obesity). 8845 (24.36%) individuals met criteria for obesity but did not meet TUD criteria (obese alone). 5170 (14.24%) individuals met criteria for a diagnosis of TUD with a BMI below 30kg/m2 (TUD alone). 20,159 (55.52%) individuals had no TUD and a BMI <30kg/m2 (Comparison). Respondents were primarily White (66.22%), with men and women representing roughly equal proportions (48.48% and 51.51% respectively).
3.2. Substance use disorders
Table 2 presents results comparing the individuals described above (Comparison, TUD, Obese, and TUD + Obesity) on past year SUDs. Relative to comparison individuals, those individuals with a TUD alone (aOR= 3.53) were significantly more likely to meet criteria for any SUD followed by individuals with TUD + obesity (aOR= 2.55). Individuals with obesity alone did not differ from comparison adults on SUDs. Similarly, when compared to comparison individuals, individuals with TUD alone (aRR = 2.60) had the greatest number of diagnosed SUDs followed by individuals with TUD + obesity (aRR = 2.19). Again, individuals with obesity alone and comparison individuals did not differ in the number of diagnosed SUDs.
Table 2.
SUD diagnosis rates.
| 1. Comparison | 2. TUD | 3. Obese | 4. TUD + Obese | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % (SE) | % (SE) | aOR | 95% CI | % (SE) | aOR | 95% CI | % (SE) | aOR | 95% CI | Contrasts | |
| Any Substance Use Disorder | 11.72 (0.35) | 35.18 (1.08) | 3.53 | 3.19; 3.91 | 9.38 (0.36) | 0.89 | 0.80; 0.99 | 26.75 (1.39) | 2.55 | 2.19; 2.96 | 2 > 4 > 1, 3 |
| Alcohol Use Disorder | 10.94 (0.33) | 30.99 (1.04) | 3.17 | 2.86; 3.51 | 8.69 (0.35) | 0.89 | 0.80; 0.99 | 23.39 (1.3) | 2.32 | 1.99; 2.70 | 2 > 4 > 1, 3 |
| Cannabis Use Disorder | 1.24 (0.09) | 8.79 (0.53) | 6.55 | 5.34; 8.03 | 1.01 (0.11) | 1.02 | 0.78; 1.34 | 6.55 (0.71) | 5.69 | 4.30; 7.53 | 2, 4 > 3, 1 |
| Other Drug | 0.44 (0.06) | 3.03 (0.29) | 0.48 | 0.04; 6.29 | 0.27 (0.05) | 1.41 | 0.47; 4.21 | 2.29 (0.459) | 2.56 | 0.43; 15.03 | NSC |
| M (SE) | M (SE) | aRR | 95% CI | M (SE) | aRR | 95% CI | M (SE) | aRR | 95% CI | Contrast | |
| Substance Use Disorders (#) | 0.12 (0.004) | 0.39 (0.01) | 2.60 | 2.43; 2.78 | 0.09 (0.004) | 0.9 | 0.83; 0.99 | 0.30 (0.02) | 2.19 | 1.96; 2.44 | 2 > 4 > 1, 3 |
Note: TUD = tobacco use disorder, aOR = adjusted odds ratio, aRR = adjusted rate ratios, NSC = no significant contrasts, SE = standard error, CI = confidence intervals, M = mean. All groups represented in the contrasts column met the significance threshold which was set at p<.05.
In examining individual substance categories, relative to comparison adults, individuals with TUD alone (aOR = 3.17) and individuals with TUD + obesity (aOR = 2.32) were significantly more likely to be diagnosed with AUD. Individuals with obesity alone did not differ from comparison individuals. Individuals with TUD alone (aOR = 6.55) and individuals with TUD + obesity (aOR = 5.69) were also significantly more likely to be diagnosed with CUD than comparison or individuals with obesity alone. There was no evidence of significant group differences in rates of other SUDs.
3.3. Comparison of mental health
Rate of diagnosis for past year mental health disorders as defined by DSM-5 criteria are described in Table 3. For the majority of disorders examined (with the exception of dysthymia, agoraphobia, specific phobia and antisocial personality disorder) there was no significant difference in prevalence rates between individuals with TUD + obesity and individuals with TUD alone. Additionally, individuals with obesity alone generally had a significantly lower likelihood of diagnosis than either individuals with TUD alone or individuals with TUD + obesity (with the exception of dysthymia); although they had higher rates of diagnosis than comparison adults.
Table 3.
Psychiatric disorder diagnosis rate.
| 1. Comparison | 2. TUD | 3. Obese | 4. TUD + Obese | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MOOD DISORDERS | % (SE) | % (SE) | aOR | 95% CI | % (SE) | aOR | 95% CI | % (SE) | aOR | 95% CI | Contrasts |
| Major Depressive Disorder | 7.91 (0.25) | 16.74 (0.69) | 2.2 | 1.94; 2.49 | 10.53 (0.41) | 1.4 | 1.26; 1.57 | 17.84 (1.15) | 2.48 | 2.07; 2.96 | 4, 2 > 3 > 1 |
| Dysthymia | 2.15 (0.12) | 5.11 (0.40) | 2 | 1.62; 2.45 | 3.36 (0.21) | 1.61 | 1.37; 1.91 | 6.17 (0.60) | 2.63 | 2.10; 3.29 | 4 > 2, 3 >1 |
| Bipolar 1 Disorder | 0.70 (0.05) | 4.02 (0.38) | 4.81 | 3.74; 6.19 | 1.20 (0.15) | 1.72 | 1.29; 2.29 | 4.88 (0.65) | 6.18 | 4.35; 8.78 | 4, 2 > 3 > 1 |
| ANXIETY DISORDERS | % (SE) | % (SE) | aOR | 95% CI | % (SE) | aOR | 95% CI | % (SE) | aOR | 95% CI | Contrasts |
| Agoraphobia | 0.90 (0.07) | 3.18 (0.33) | 3.23 | 2.37; 4.41 | 1.53 (0.17) | 1.72 | 1.32; 2.25 | 3.22 (0.69) | 3.36 | 2.11; 5.35 | 4, 2 > 3 > 1 |
| Panic Disorder | 1.82 (0.12) | 6.65 (0.38) | 3.37 | 2.85; 3.98 | 2.83 (0.24) | 1.54 | 1.25; 1.90 | 7.13 (0.77) | 3.64 | 2.81; 4.71 | 4, 2 > 3 > 1 |
| Social Phobia | 2.06 (0.14) | 4.95 (0.32) | 1.96 | 1.65; 2.34 | 2.86 (0.22) | 1.34 | 1.12; 1.60 | 5.21 (0.58) | 2.15 | 1.63; 2.84 | 4, 2 > 3 > 1 |
| Specific Phobia | 4.61 (0.21) | 8.47 (0.43) | 1.8 | 1.55; 2.09 | 6.16 (0.33) | 1.33 | 1.12; 1.57 | 7.67 (0.68) | 1.59 | 1.29; 1.95 | 2 > 3, 4 > 1 |
| Generalized Anxiety Disorder | 3.76 (0.17) | 9.10 (0.43) | 2.52 | 2.21; 2.88 | 5.47 (0.27) | 1.53 | 1.33; 1.75 | 10.16 (0.96) | 2.92 | 2.32; 3.67 | 4, 2 > 3 > 1 |
| Posttraumatic Stress Disorder | 2.96 (0.15) | 8.82 (0.58) | 2.71 | 2.25; 3.26 | 4.74 (0.26) | 1.55 | 1.32; 1.82 | 10.54 (0.80) | 3.3 | 2.72; 4.01 | 4, 2 > 3 > 1 |
| PERSONALITY DISORDERS | % (SE) | % (SE) | aOR | 95% CI | % (SE) | aOR | 95% CI | % (SE) | aOR | 95% CI | Contrasts |
| Schizotypal Personality Disorder | 2.80 (0.14) | 9.32 (0.52) | 2.59 | 2.25; 2.98 | 3.93 (0.223) | 1.34 | 1.15; 1.56 | 9.40 (0.86) | 2.73 | 2.14; 3.48 | 4, 2 > 3 > 1 |
| Borderline Personality Disorder | 6.19 (0.22) | 21.99 (0.84) | 3.23 | 2.90; 3.60 | 9.01 (0.44) | 1.43 | 1.27; 1.62 | 23.21 (1.17) | 3.6 | 3.06; 4.24 | 4, 2 > 3 > 1 |
| Antisocial Personality Disorder | 1.37 (0.12) | 6.95 (0.48) | 3.51 | 2.90; 4.25 | 1.90 (0.15) | 1.28 | 1.02; 1.61 | 6.47 (0.78) | 3.37 | 2.41; 4.72 | 4, 2 > 3 > 1 |
| % (SE) | % (SE) | aRR | 95% CI | % (SE) | aRR | 95% CI | % (SE) | aRR | 95% CI | Contrasts | |
| Mental Health Disorders (#) | 0.37 (0.01) | 1.05 (0.03) | 2.38 | 2.22; 2.55 | 0.53 (0.02) | 1.4 | 1.31; 1.51 | 1.12 (0.05) | 2.59 | 2.33; 2.87 | 4, 2 > 3 > 1 |
Note: TUD = tobacco use disorder, aOR = adjusted odds ratio, aRR = adjusted rate ratios, NSC = no significant contrasts, SE = standard error, CI = confidence intervals, M = mean. All groups represented in the contrasts column met the significance threshold which was set at p<.05.
For dysthymia, relative to comparison individuals, individuals with TUD + obesity (aOR = 2.33), individuals with TUD alone (aOR = 1.83), and individuals with obesity alone (aOR = 1.54) all had a higher likelihood of diagnosis. Additionally individuals with TUD + obesity had a greater likelihood of diagnosis than individuals with obesity alone, but not individuals with TUD alone. For agoraphobia, relative to comparison individuals, individuals with TUD alone (aOR = 2.87), individuals with TUD + obesity (aOR = 2.8), and individuals with obesity alone (aOR = 1.65) all had a higher likelihood of diagnosis. Additionally individuals with TUD alone had a greater likelihood of diagnosis than individuals with obesity alone, but not individuals with TUD + obesity. For specific phobia, relative to comparison individuals, individuals with TUD alone (aOR = 1.78), individuals with TUD + obesity (aOR = 1.57), and individuals with obesity alone (aOR = 1.33) all had a higher likelihood of diagnosis. Additionally individuals with TUD alone had a greater likelihood of diagnosis than individuals with obesity alone, but not individuals with TUD + obesity. For antisocial personality disorder, individuals with TUD alone (aOR = 3.17) and individuals with TUD + obesity (aOR = 2.95) had a higher likelihood of diagnosis than both individuals with obesity alone (aOR=1.26) and comparison individuals. Finally, individuals with TUD + obesity (aRR = 2.38) and individuals with TUD alone (aRR = 2.24) experienced the highest rates of mental health disorders, followed by individuals with obesity alone (aRR = 1.4), and then comparison adults
4. Discussion
The current study aimed to document substance use and psychiatric comorbidities among people with TUD, obesity, and the combination of these health conditions. Consistent with our hypotheses, we found that people with obesity, including those with TUD, had lower rates of comorbid SUD diagnosis than those with TUD alone. These findings are consistent with other studies that investigated the relationship between obesity and the development of SUDs (Healton et al., 2006; Dare et al., 2015; Gearhardt et al., 2012, 2018). For instance, Pickering et al. (2011) found in Waves I and II of the NESARC that a higher BMI was inversely related with AUD risk. Evidence also supports the reduction of comorbid SUDs even in the presence of TUD. In fact, Roberts and Rosenheck (2020) found that veterans treated in VHA with class 3 obesity (those who were at a BMI ≥ 40kg/m2) with or without a TUD were less likely to be diagnosed with another SUD compared to those of healthy weight who used tobacco. Both of these reports, along with the current findings, support the notion that obesity reduces the risk of the development of substance use problems, even among people who possess other risk factors (e.g., tobacco use). Finally, participants with TUD but no obesity had the comparatively highest rate of comorbid SUD diagnosis, consistent with previous studies showing that TUD is a major risk factor for SUD's (Mckee et al., 2007; Smith et al., 2014; John et al., 2018).
The precise mechanisms behind the lower rates of substance use disorders (SUD) in individuals with obesity remain somewhat elusive. It is believed that both conditions share similar neurobiological circuits that contribute to their development (Volkow and Wise, 2005; Volkow et al., 2011). This commonality may create a competitive relationship between rewarding food and substances of abuse, potentially reducing the need for one when the other is present (Kleiner et al., 2004; Warren and Gold, 2007; Nolan, 2013; Sansone and Sansone, 2013; Michaud et al., 2017). This phenomenon is often referred to as the food-drug competition hypothesis (Cummings et al., 2015; Gearhardt et al., 2012, 2018). The competition appears to be centered around dopaminergic reward pathways involved in reinforcement, decision-making, craving, and delay discounting (Volkow and Baler, 2015; Poisson et al., 2021). This food-drug competition hypothesis may explain why, in the current study, individuals with obesity had the lowest rate of comorbid SUD diagnoses.
However, among those with both conditions, the rate of comorbid SUDs was lower than in those with a tobacco use disorder (TUD) alone but still significantly higher than in those with obesity alone. Obesity might contribute to a reduction in comorbid SUDs through food-drug competition, but it is possible that these individuals have a dysregulated reward pathway (Reynolds, 2006; Stanger et al., 2013; Rupprecht et al., 2015), where the competition between food and drugs exists but is less prominent. Further research is clearly needed to disentangle the association between obesity and SUD risk.
We found limited support for our hypothesis that people with TUD and obesity would show higher rates of psychiatric comorbidity. Generally, these individuals did have the highest rates of psychiatric disorders when compared to others in our analyses, but the difference between them and those expressing only a TUD was mostly non-significant (with the exception of dysthymia). Additionally, the reduced risk conferred by obesity regarding the development of SUDs does not appear to extend beyond SUDs into other categories of behavioral health. Indeed, we found that people who meet obesity criteria are at a higher risk for most psychiatric disorders compared to those of healthy weight, consistent with prior research (for review see Blüher, 2019; Skou et al., 2022). Obesity and TUD individually are associated with an increased prevalence of mental health conditions (Simon et al., 2006; Smith et al., 2014) with TUD more often co-occurring with multiple mental health disorders (Prochaska et al., 2017). However, comorbid expression of these conditions, or any comorbidity, appears to make mental health issues worse (Roberts and Rosenheck, 2020; Skou et al., 2022). Perhaps the use of BMI as a dichotomous classification of obese or not in the current study may have limited findings, as the relationship between BMI, TUD, and other conditions may be more nuanced (Rupprecht et al., 2015). For instance, a U-shaped relationship between BMI and TUD has been observed, where those with either low or high BMI had higher rates of TUD, while those with moderate BMI had lower rates (Chatkin et al., 2010). Therefore, comparing only healthy weight (BMI ≤ 29kg/m2) and people with obesity (BMI ≥ 30kg/m2) may oversimplify the relationship. Furthermore, the amount of smoking may also play a role in the relationship between TUD and mental health, as those who consume the most cigarettes often have more severe mental health conditions (Prochaska et al., 2017; Smith et al., 2014). Further research is needed to address these questions, however, it is clear that clinical guidelines should continue to focus on serving individuals who either express or are at risk for multimorbidities because it commonly leads to worse outcomes for the patients over the lifespan.
This study builds on Roberts and Rosenheck (2020) by further examining the relationship between multimorbid obesity, TUD, and the development of SUD and other psychiatric conditions. The previous study had limitations due to its reliance on VHA health records, potentially reducing generalizability (Vassar and Holzmann, 2013). In contrast, the current study used the NESARC-III which relies on a systematic, representative sampling strategy and used the gold-standard AUDADIS survey instrument. Moreover, it included a comparison/control group and defined obesity as class 1 or greater (BMI > 30kg/m2), possibly contributing to the differences in findings. However, the consistent results related to SUD across methodologies demonstrate the robustness of these findings (Roberts and Rosenheck, 2020).
This study offers valuable insights into the health risks of obesity and TUD but has some limitations. The cross-sectional data prevents direct exploration of underlying mechanisms, requiring longitudinal or human laboratory studies for clarification (Buis and Van Roosmalen, 2021). Additionally, the use of BMI as the primary indicator of dysregulated eating behaviors may limit understanding, as it does not encompass all potential variables affecting body fat (Rothman, 2008; Nuttall, 2015). Future studies could benefit from more comprehensive measures. However, BMI is practical for large-scale population studies (Gutin, 2018). We elected to operationalize obesity categorically in the current study to support direct clinical translation of our findings. There may, however, be advantages to treating BMI continuously in terms of uncovering more nuanced associations between obesity and behavioral health conditions (Lohse et al., 2017). In regards to the data, NESARC-III has been criticized as potentially overestimating the rate of SUD in the population (Caetano, 2015), which may result in overestimation of rates of multimorbidity in the cohorts we examined here. Lastly, NESARC-III data was collected in 2012–2013, and population-level shifts in outcomes may have occurred since then.
5. Conclusions
This study demonstrates that obesity is associated with a decreased risk of developing SUD, even in individuals with other risk factors, but is still associated with other health-related disorders. These findings have implications for targeted prevention efforts and intervention development for treating obesity, SUD's, or both. Clinicians may use this information to tailor treatment plans, considering the potential development of additional SUDs and psychiatric disorders in those with either or both conditions. As multimorbidities contribute to poorer health outcomes, especially in low SES communities, understanding risk factors and providing comprehensive treatment is crucial, particularly considering that obesity rates appear to be on the rise (Skou et al., 2022; Aggarwal et al., 2023). These results also provide further evidence for the food-drug competition hypothesis which lends additional support for a unique diagnostic category for food addiction. However, future studies employing pre-clinical, clinical, or longitudinal methods are needed to investigate the mechanisms of these associations. Further characterization of the relationships, risk factors, and temporal dynamics between obesity and SUD could help elucidate the complex interaction between these conditions and inform clinical practice.
Funding source
This work was supported by NIAAA grants K01AA025670 (TLV), R03AA028361 (TLV), K23AA026890 (WR), U54AA027989 (SAM), and a VA VISN1 CDA and PASA (2022RFA6a; MRP).
Declaration of Competing Interest
Given her role as Associate Editor, Sherry McKee, PhD had no involvement in the peer-review of this article and has no access to information regarding its peer-review. Full responsibility for the editorial process for this article was provided by Teri Franklin, PhD.
Footnotes
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.dadr.2023.100162.
Appendix. Supplementary materials
References
- Aggarwal R., Yeh R.W., Joynt Maddox K.E., Wadhera R.K. Cardiovascular risk factor prevalence, treatment, and control in US adults aged 20 to 44 years, 2009 to march 2020. JAMA. 2023 doi: 10.1001/jama.2023.2307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Atun R. Transitioning health systems for multimorbidity. Lancet. 2015;386(9995):721–722. doi: 10.1016/S0140-6736(14)62254-6. [DOI] [PubMed] [Google Scholar]
- Audrain-McGovern J., Benowitz N. Cigarette smoking, nicotine, and body weight. Clin. Pharmacol. Ther. 2011;90(1):164–168. doi: 10.1038/clpt.2011.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Avena N.M., Gearhardt A.N., Gold M.S., Wang G.-.J., Potenza M.N. Tossing the baby out with the bathwater after a brief rinse? The potential downside of dismissing food addiction based on limited data. Nat. Rev. Neurosci. 2012;13(7) doi: 10.1038/nrn3212-c1. [DOI] [PubMed] [Google Scholar]
- Azam H., Shahrestani S., Phan K. Alcohol use disorders before and after bariatric surgery: a systematic review and meta-analysis. Ann. Transl. Med. 2018;6(8):148. doi: 10.21037/atm.2018.03.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Barry D., Clarke M., Petry N.M. Obesity and its relationship to addictions: is overeating a form of addictive behavior? Am. J. Addict. 2009;18(6):439–451. doi: 10.3109/10550490903205579. /American Academy of Psychiatrists in Alcoholism and Addictions. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Benowitz N.L. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu. Rev. Pharmacol. Toxicol. 2009;49:57–71. doi: 10.1146/annurev.pharmtox.48.113006.094742. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Berthoud H.-.R. Multiple neural systems controlling food intake and body weight. Neurosci. Biobehav. Rev. 2002;26(4):393–428. doi: 10.1016/S0149-7634(02)00014-3. [DOI] [PubMed] [Google Scholar]
- Bhalla I.P., Stefanovics E.A., Rosenheck R.A. Mental health multimorbidity and poor quality of life in patients with schizophrenia. Schizophr. Res. 2018;201:39–45. doi: 10.1016/j.schres.2018.04.035. [DOI] [PubMed] [Google Scholar]
- Blüher Matthias. Obesity: global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 2019;15(5):5. doi: 10.1038/s41574-019-0176-8. [DOI] [PubMed] [Google Scholar]
- Buis D.T.P., van Roosmalen J. Turtles all the way down: do biological mechanisms for epidemiological observations always matter? Eur. J. Epidemiol. 2021;36(9):909–912. doi: 10.1007/s10654-021-00807-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Caetano R. A decade after NESARC: what has it told us? Addiction. 2015;110(3):375–377. doi: 10.1111/add.12627. [DOI] [PubMed] [Google Scholar]
- Centers for Disease Control and Prevention (CDC). (2022). National center for chronic disease prevention and health promotion, division of nutrition, physical activity, and obesity. https://www.cdc.gov/nccdphp/dnpao/index.html.
- CDCTobaccoFree . Centers for Disease Control and Prevention; 2021. 2014 SGR: The Health Consequences of Smoking—50 Years of Progress.https://www.cdc.gov/tobacco/sgr/50th-anniversary/index.htm [Google Scholar]
- Centers for Disease Control and Prevention. (2020). Defining adult overweight and obesity. Retrieved from https://www.cdc.gov/obesity/adult/defining.html.
- Centers for Disease Control and Prevention (US), National Center for Chronic Disease Prevention and Health Promotion (US), & Office on Smoking and Health (US) Centers for Disease Control and Prevention (US); 2010. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis For Smoking-Attributable Disease: A Report of the Surgeon General.http://www.ncbi.nlm.nih.gov/books/NBK53017/10.1056/NEJMsa0900459 [PubMed] [Google Scholar]
- Chatkin R., Mottin C.C., Chatkin J.M. Smoking among morbidly obese patients. BMC Pulm. Med. 2010;10:61. doi: 10.1186/1471-2466-10-61. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cummings J.R., Ray L.A., Tomiyama A.J. Food-alcohol competition: as young females eat more food, do they drink less alcohol? J. Health Psychol. 2015;20(7):1022–1032. doi: 10.1177/1359105315611955. [DOI] [PubMed] [Google Scholar]
- Dare S., Mackay D.F., Pell J.P. Relationship between smoking and obesity: a cross-sectional study of 499,504 middle-aged adults in the UK general population. PLoS One. 2015;10(4) doi: 10.1371/journal.pone.0123579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fortin M., Lapointe L., Hudon C., Vanasse A., Ntetu A.L., Maltais D. Multimorbidity and quality of life in primary care: a systematic review. Health Qual. Life Outcomes. 2004;2:51. doi: 10.1186/1477-7525-2-51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fortin M., Bravo G., Hudon C., Lapointe L., Dubois M.-.F., Almirall J. Psychological distress and multimorbidity in primary care. Ann. Fam. Med. 2006;4(5):417–422. doi: 10.1370/afm.528. [DOI] [PMC free article] [PubMed] [Google Scholar]
- GBD 2019 Diseases and Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–1222. doi: 10.1016/S0140-6736(20)30925-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gearhardt A.N., Harrison E.L.R., McKee S.A. Does co-morbid depression alter the inverse relationship between obesity and substance use disorders? Drug Alcohol. Depend. 2012;124(1–2):185–188. doi: 10.1016/j.drugalcdep.2012.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gearhardt A.N., Waller R., Jester J.M., Hyde L.W., Zucker R.A. Body mass index across adolescence and substance use problems in early adulthood. Psychol. Addict. Behav. 2018;32(3):309–319. doi: 10.1037/adb0000365. Journal of the Society of Psychologists in Addictive Behaviors. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Grant, B.F., Chu, A., Sigman, R., Amsbary, M., Kali, J., Sugawara, Y., & Goldstein, R., (2014). Source and accuracy statement: national epidemiologic survey on alcohol and related conditions-III (NESARC-III). Rockville, MD: National Institute on Alcohol Abuse and Alcoholism, 1–125.
- Gutin I. In BMI we trust: reframing the body mass index as a measure of health. Soc. Theory & Health: STH. 2018;16(3):256–271. doi: 10.1057/s41285-017-0055-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Han B.H., Termine D.J., Moore A.A., Sherman S.E., Palamar J.J. Medical multimorbidity and drug use among adults in the United States. Prev. Med. Rep. 2018;12:214–219. doi: 10.1016/j.pmedr.2018.10.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hasin D.S., Greenstein E., Aivadyan C., Stohl M., Aharonovich E., Saha T., Goldstein R., Nunes E.V., Jung J., Zhang H., Grant B.F. The alcohol use disorder and associated disabilities interview schedule-5 (AUDADIS-5): procedural validity of substance use disorders modules through clinical re-appraisal in a general population sample. Drug Alcohol. Depend. 2015;148:40–46. doi: 10.1016/j.drugalcdep.2014.12.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Healton C.G., Vallone D., McCausland K.L., Xiao H., Green M.P. Smoking, obesity, and their co-occurrence in the United States: cross sectional analysis. BMJ: Br. Med. J. 2006;333(7557):25–26. doi: 10.1136/bmj.38840.608704.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hoover L.V., Yu H.P., Cummings J.R., Ferguson S.G., Gearhardt A.N. Co-occurrence of food addiction, obesity, problematic substance use, and parental history of problematic alcohol use. Psychol. Addict. Behav. 2022 doi: 10.1037/adb0000870. No Pagination Specified-No Pagination Specified. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ivezaj V., Saules K.K., Wiedemann A.A. I didn't see this coming.”: why are postbariatric patients in substance abuse treatment? Patients’ perceptions of etiology and future recommendations. Obes. Surg. 2012;22(8):1308–1314. doi: 10.1007/s11695-012-0668-2. [DOI] [PubMed] [Google Scholar]
- John W.S., Zhu H., Mannelli P., Schwartz R.P., Subramaniam G.A., Wu L.-.T. Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients. Drug Alcohol. Depend. 2018;187:79–87. doi: 10.1016/j.drugalcdep.2018.01.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Katikireddi S.V., Skivington K., Leyland A.H., Hunt K., Mercer S.W. The contribution of risk factors to socioeconomic inequalities in multimorbidity across the lifecourse: a longitudinal analysis of the Twenty-07 cohort. BMC Med. 2017;15(1):152. doi: 10.1186/s12916-017-0913-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kim H.S., Hodgins D.C., Garcia X., Ritchie E.V., Musani I., McGrath D.S., von Ranson K.M. A systematic review of addiction substitution in recovery: clinical lore or empirically-based? Clin. Psychol. Rev. 2021;89 doi: 10.1016/j.cpr.2021.102083. [DOI] [PubMed] [Google Scholar]
- Kleiner K.D., Gold M.S., Frostpineda K., Lenzbrunsman B., Perri M.G., Jacobs W.S. Body mass index and alcohol use. J. Addict. Dis. 2004;23(3):105–118. doi: 10.1300/J069v23n03_08. [DOI] [PubMed] [Google Scholar]
- Lohse T., Rohrmann S., Faeh D., Hothorn T. Continuous outcome logistic regression for analyzing body mass index distributions. F1000Res. 2017;6:1933. doi: 10.12688/f1000research.12934.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Luppino F.S., de Wit L.M., Bouvy P.F., Stijnen T., Cuijpers P., Penninx B.W.J.H., Zitman F.G. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch. Gen. Psychiatry. 2010;67(3):220–229. doi: 10.1001/archgenpsychiatry.2010.2. [DOI] [PubMed] [Google Scholar]
- Mather A.A., Cox B.J., Enns M.W., Sareen J. Associations of obesity with psychiatric disorders and suicidal behaviors in a nationally representative sample. J. Psychosom. Res. 2009;66(4) doi: 10.1016/j.jpsychores.2008.09.008. Article 4. [DOI] [PubMed] [Google Scholar]
- McKee S.A., Falba T., O'Malley S.S., Sindelar J., O'Connor P.G. Smoking status as a clinical indicator for alcohol misuse in US adults. Arch. Intern. Med. 2007;167(7):716–721. doi: 10.1001/archinte.167.7.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Michaud A., Vainik U., Garcia-Garcia I., Dagher A. Overlapping neural endophenotypes in addiction and obesity. Front. Endocrinol. 2017;8:127. doi: 10.3389/fendo.2017.00127. (Lausanne) [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nolan L.J. Shared urges? The links between drugs of abuse, eating, and body weight. Curr. Obes. Rep. 2013;2(2):150–156. doi: 10.1007/s13679-013-0048-9. [DOI] [Google Scholar]
- Nuttall F.Q. Body mass index. Nutr. Today. 2015;50(3):117–128. doi: 10.1097/NT.0000000000000092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pickering R.P., Goldstein R.B., Hasin D.S., Blanco C., Smith S.M., Huang B., Pulay A.J., Ruan W.J., Saha T.D., Stinson F.S., Dawson D.A., Chou S.P., Grant B.F. Temporal relationships between overweight and obesity and DSM-IV substance use, mood, and anxiety disorders: results from a prospective study, the national epidemiologic survey on alcohol and related conditions. J. Clin. Psychiatry. 2011;72(11):1494–1502. doi: 10.4088/JCP.10m06077gry. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Poisson C.L., Engel L., Saunders B.T. Dopamine circuit mechanisms of addiction-like behaviors. Front. Neural. Circ. 2021;15 doi: 10.3389/fncir.2021.752420. https://www.frontiersin.org/articles/10.3389/fncir.2021.752420 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Powell-Wiley T.M., Poirier P., Burke L.E., Després J.-.P., Gordon-Larsen P., Lavie C.J., Lear S.A., Ndumele C.E., Neeland I.J., Sanders P., St-Onge M.-.P. Obesity and cardiovascular disease: a scientific statement from the American heart association. Circulation. 2021;143(21):e984–e1010. doi: 10.1161/CIR.0000000000000973. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Prochaska J.J., Das S., Young-Wolff K.C. Smoking, mental illness, and public health. Annu. Rev. Public Health. 2017;38(1):165–185. doi: 10.1146/annurev-publhealth-031816-044618. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Read J.R., Sharpe L., Modini M., Dear B.F. Multimorbidity and depression: a systematic review and meta-analysis. J. Affect. Disord. 2017;221:36–46. doi: 10.1016/j.jad.2017.06.009. [DOI] [PubMed] [Google Scholar]
- Reynolds B. A review of delay-discounting research with humans: relations to drug use and gambling. Behav. Pharmacol. 2006;17(8):651. doi: 10.1097/FBP.0b013e3280115f99. [DOI] [PubMed] [Google Scholar]
- Roberts W., Rosenheck R.A. Correlates of concurrent morbid obesity and tobacco use disorder nationally in the veterans health administration. J. Dual. Diagn. 2020;16(4):4. doi: 10.1080/15504263.2020.1808749. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rothman K.J. BMI-related errors in the measurement of obesity. Int. J. Obes. 2008;32(3) doi: 10.1038/ijo.2008.87. [DOI] [PubMed] [Google Scholar]
- Rupprecht L.E., Donny E.C., Sved A.F. Obese smokers as a potential subpopulation of risk in tobacco reduction policy. Yale J. Biol. Med. 2015;88(3):289–294. [PMC free article] [PubMed] [Google Scholar]
- Salisbury C. Multimorbidity: redesigning health care for people who use it. Lancet. 2012;380(9836):7–9. doi: 10.1016/S0140-6736(12)60482-6. [DOI] [PubMed] [Google Scholar]
- SAMHSA, (2021). 2020 national survey of drug use and health (NSDUH) releases | CBHSQ data. 2021. https://www.samhsa.gov/data/release/2020-national-survey-drug-use-and-health-nsduh-releases.
- Sansone R.A., Sansone L.A. Obesity and substance misuse: is there a relationship? Innov. Clin. Neurosci. 2013;10(9–10) [PMC free article] [PubMed] [Google Scholar]
- Schulte M.T., Hser Y.-.I. Substance use and associated health conditions throughout the lifespan. Public Health Rev. 2014;35(2) doi: 10.1007/BF03391702. https://web-beta.archive.org/web/20150206061220/http://www.publichealthreviews.eu/upload/pdf_files/14/00_Schulte_Hser.pdf [DOI] [PMC free article] [PubMed] [Google Scholar]
- Scott K.M., Bruffaerts R., Simon G.E., Alonso J., Angermeyer M., de Girolamo G., Demyttenaere K., Gasquet I., Haro J.M., Karam E., Kessler R.C., Levinson D., Mora M.E.M., Browne M.O., Ormel J.H., Villa J.P., Uda H., Von Korff M. Obesity and mental disorders in the general population: results from the world mental health surveys. Int. J. Obes. 2008;32(1):192–200. doi: 10.1038/sj.ijo.0803701. (Lond) [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shaffer H.J., LaPlante D.A., LaBrie R.A., Kidman R.C., Donato A.N., Stanton M.V. Toward a syndrome model of addiction: multiple expressions, common etiology. Harvard Rev. Psychiatry. 2004;12(6):367–374. doi: 10.1080/10673220490905705. [DOI] [PubMed] [Google Scholar]
- Simon G.E., Von Korff M., Saunders K., Miglioretti D.L., Crane P.K., van Belle G., Kessler R.C. Association between obesity and psychiatric disorders in the US adult population. Arch. Gen. Psychiatry. 2006;63(7):824–830. doi: 10.1001/archpsyc.63.7.824. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Skou S.T., Mair F.S., Fortin M., Guthrie B., Nunes B.P., Miranda J.J., Boyd C.M., Pati S., Mtenga S., Smith S.M. Multimorbidity. Nat. Rev. Dis. Prim. 2022;8(1):1. doi: 10.1038/s41572-022-00376-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smith P.H., Mazure C.M., McKee S.A. Smoking and mental illness in the U.S. population. Tob. Control. 2014;23(e2):e147–e153. doi: 10.1136/tobaccocontrol-2013-051466. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stanger C., Elton A., Ryan S.R., James G.A., Budney A.J., Kilts C.D. Neuroeconomics and adolescent substance abuse: individual differences in neural networks and delay discounting. J. Am. Acad. Child Adolesc. Psychiatry. 2013;52(7):747–755. doi: 10.1016/j.jaac.2013.04.013. e6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vasiliu O. Current status of evidence for a new diagnosis: food addiction-a literature review. Front. Psychiatry. 2022;12 doi: 10.3389/fpsyt.2021.824936. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vassar M., Holzmann M. The retrospective chart review: important methodological considerations. J. Educ. Eval. Health Prof. 2013;10:12. doi: 10.3352/jeehp.2013.10.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Volkow N.D., Wise R.A. How can drug addiction help us understand obesity? Nat. Neurosci. 2005;8(5):5. doi: 10.1038/nn1452. [DOI] [PubMed] [Google Scholar]
- Volkow N.D., Wang G.-.J., Baler R.D. Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn. Sci. (Regul. Ed.) 2011;15(1):1. doi: 10.1016/j.tics.2010.11.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Volkow N.D., Baler R.D. NOW vs LATER brain circuits: implications for obesity and addiction. Trends Neurosci. 2015;38(6):6. doi: 10.1016/j.tins.2015.04.002. [DOI] [PubMed] [Google Scholar]
- Warren M.W., Gold M.S. The relationship between obesity and drug use. Am. J. Psychiatry. 2007;164(8) doi: 10.1300/J069v23n03_04. [DOI] [PubMed] [Google Scholar]
- Weinberger A.H., Platt J., Esan H., Galea S., Erlich D., Goodwin R.D. Cigarette smoking is associated with increased risk of substance use disorder relapse: a nationally representative, prospective longitudinal investigation. J. Clin. Psychiatry. 2017;78(2):e152–e160. doi: 10.4088/JCP.15m10062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- White M.A., McKee S.A., O'Malley S.S. Smoke and mirrors: magnified beliefs that cigarette smoking suppresses weight. Addict. Behav. 2007;32(10):2200–2210. doi: 10.1016/j.addbeh.2007.02.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- White M.A. Smoking for weight control and its associations with eating disorder symptomatology. Compr. Psychiatry. 2012;53(4):403–407. doi: 10.1016/j.comppsych.2011.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- World Health Organization. (2021). Obesity and overweight. Retrieved February 16, 2023, from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
